Tykerb contains Lapatinib, an oral targeted anticancer medicine belonging to the tyrosine kinase inhibitor (TKI) class. Lapatinib inhibits the intracellular tyrosine kinase activity of HER2 (ErbB2) and EGFR (ErbB1), interfering with signaling pathways involved in the growth and survival of certain cancer cells.

Lapatinib is primarily used in combination with other anticancer medicines for selected patients with HER2-positive advanced or metastatic breast cancer. It is a prescription medicine and should be used under the supervision of an oncologist.

What is Lapatinib?

Lapatinib is a dual EGFR/HER2 tyrosine kinase inhibitor. It works by blocking signaling from HER2 and EGFR receptors, which can reduce proliferation and survival signaling in susceptible tumor cells.

Lapatinib has been used in treatment regimens for HER2-positive advanced or metastatic breast cancer, including combination therapy with medicines such as capecitabine or trastuzumab in appropriate patients.

Benefits and Uses of Tykerb

Tykerb (Lapatinib) may be prescribed for:

• Treatment of selected HER2-positive advanced or metastatic breast cancer
• Use in combination with capecitabine in appropriate treatment settings
• Use in combination with trastuzumab for selected patients
• Inhibition of HER2-mediated cancer-cell signaling
• Targeted treatment based on the molecular characteristics of the tumor

The appropriate treatment regimen depends on the patient’s HER2 status, previous treatments, disease progression, and clinical condition.

Dosage Guidelines

The dosage of Lapatinib depends on the specific treatment regimen and combination medicine being used.

• Take Tykerb exactly as prescribed by the treating oncologist.
• Lapatinib is administered orally, generally once daily in approved breast-cancer regimens.
• Tablets should be swallowed whole with water.
• Lapatinib should generally be taken at least one hour before or at least one hour after food, according to product instructions.
• The prescribed dose should not be changed without medical advice.
• If a dose is missed, follow the instructions provided by the treating healthcare professional rather than taking an extra dose.

Liver function and cardiac function may require monitoring during treatment.

Wholesale & Supply

Onco India International can support wholesale and bulk pharmaceutical supply of Tykerb (Lapatinib) for eligible markets and pharmaceutical procurement requirements.

Bulk supply may be suitable for:

• Pharmaceutical distributors
• Hospitals and healthcare institutions
• Oncology distributors
• International pharmaceutical buyers
• Licensed importers and exporters
• Healthcare procurement organizations

Packaging, minimum order quantities, documentation, and availability may vary according to market requirements.

Buying Lapatinib Online

When sourcing Tykerb or other Lapatinib products, buyers should verify the strength, dosage form, manufacturer, batch information, packaging, and applicable quality documentation.

Lapatinib is a prescription anticancer medicine. Pharmaceutical products should be obtained through authorized and appropriately licensed suppliers and used under qualified medical supervision.

Reviews

Individual responses to Lapatinib may vary depending on HER2 status, cancer stage, previous therapies, combination treatment, and patient-specific factors.

For pharmaceutical procurement, important considerations include product quality, manufacturing standards, documentation, packaging integrity, and supply reliability.

Quality Assurance

Quality assurance is essential for targeted oncology medicines such as Lapatinib. Products should be manufactured, tested, packaged, and stored according to applicable pharmaceutical quality and regulatory requirements.

Relevant documentation, including available product specifications, certificates, batch information, and package inserts, can be requested where applicable.

Frequently Asked Questions

What is Tykerb used for?

Tykerb contains Lapatinib and is used in selected treatment regimens for HER2-positive advanced or metastatic breast cancer.

What type of medicine is Lapatinib?

Lapatinib is a tyrosine kinase inhibitor (TKI) that targets HER2 and EGFR signaling.

How does Lapatinib work?

Lapatinib inhibits the intracellular tyrosine kinase activity of HER2 and EGFR, disrupting signaling pathways that can promote cancer-cell growth and survival.

Is Lapatinib used for HER2-positive breast cancer?

Yes. Lapatinib is used in selected patients with HER2-positive advanced or metastatic breast cancer, generally as part of a combination treatment regimen.

How is Lapatinib administered?

Lapatinib is taken orally, generally once daily in approved breast-cancer regimens. The exact dose depends on the treatment combination and prescribing information.

Should Lapatinib be taken with food?

Lapatinib is generally taken on an empty stomach, at least one hour before or at least one hour after food. Patients should follow the specific product instructions provided by their healthcare professional.

What are common side effects of Lapatinib?

Possible adverse effects include diarrhea, nausea, vomiting, rash, hand-foot syndrome, fatigue, and changes in liver function. Serious adverse effects can also occur.

Can Lapatinib affect the heart?

Yes. Lapatinib can affect cardiac function in some patients. Healthcare professionals may assess cardiac function before and during treatment when clinically appropriate.

Can Lapatinib affect the liver?

Yes. Lapatinib can cause liver injury, including serious hepatotoxicity in rare cases. Liver-function monitoring may therefore be required.

Conclusion

Tykerb (Lapatinib) is an oral targeted anticancer medicine that inhibits HER2 and EGFR tyrosine kinase signaling. It is used in selected treatment regimens for HER2-positive advanced or metastatic breast cancer.

Because treatment selection, combination therapy, and monitoring depend on the patient’s disease characteristics and previous treatment, Lapatinib should be prescribed and monitored by a qualified oncology professional.